News

Azenta, Inc.'s (NASDAQ:AZTA) Intrinsic Value Is Potentially 44% Above Its Share Price
The projected fair value for Azenta is US$36.39 based on 2 Stage Free Cash Flow to Equity. Azenta is estimated to be 31% undervalued based on current share price of ...
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Intrinsic Value Is Potentially 65% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Cosmo Pharmaceuticals fair value estimate is CHF80.81 ...